Technology & Software Global On demand · 24-48h

Global Biomanufacturing and Fermentation Service Market Strategic Research Report

Global Biomanufacturing and Fermentation Service Market Stra…
$3,500 USD
Market Research Reports
Strategic Research Report
Global Biomanufacturing and Fermentation Service Market
$8.38B2025
15.1%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Strain Engineering Services, Fermentation Process Optimization, Analytical Testing & Quality Control Services, Fermentation CDMO Service

By Application: Biopharmaceuticals, Industrial Biotechnology, Food and Functional Ingredients, Others

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: FUJIFILM Biotechnologies, Elise Biopharma, BOC Sciences, Isomerase Therapeutics, AGC Biologics, Centre for Process Innovation (CPI), Euroapi, 3PBIOVIAN, Abolis Biotechnologies, Evonik, ScaleUp Bio Pte Ltd, Olon Biotech, Biocatalysts Ltd, Manus Bio, ADM, Bio‑Technical Resources, GEA, Lonza, WuXi Biologics, Ajinomoto, BIOVECTRA Inc., Nordmark Pharma GmbH, Dakota BioWorx, Andgel Industrial (Shanghai) Co, Chengdu Yingde Biomedical, Thermo Fisher Scientific, Asymchem, Danaher, Sartorius, Laurus Bio

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 161 pages
Market size 2025
$8.38B
Billion USD
Forecast CAGR
15.1%
2025-2032
Forecast 2032
$22.4B
Projected
Régions
5
Asia Pacific · Latin America · MEA · Europe · North America

Vue d'ensemble

Scope of the Report

The global Biomanufacturing and Fermentation Service market size is predicted to grow from US$ 8,376 million in 2025 to US$ 22,221 million in 2032; it is expected to grow at a CAGR of 15.1% from 2026 to 2032.

Biomanufacturing and fermentation services are a crucial supporting link in the modern biopharmaceutical and biotechnology industries. Their core lies in controlling the large-scale cultivation and production of microorganisms or cells under controlled environments to obtain target proteins, antibodies, vaccines, or functional biomolecules. The upstream fermentation stage involves cell line resuscitation, passage culture, and scale-up culture in large-scale bioreactors to ensure the expression and accumulation of the target product. The downstream purification stage uses processes such as filtration, chromatography, and virus inactivation to separate the target product from impurities in the fermentation broth, obtaining a high-purity stock solution. Biomanufacturing and fermentation services emphasize continuity and process controllability, and are widely used in the production of monoclonal antibodies, vaccines, recombinant proteins, and precisely fermented food ingredients. They rely on specialized equipment, consumables, and a rigorous quality management system to ensure product consistency and safety.

Global key Biomanufacturing and Fermentation Service players cover FUJIFILM Biotechnologies, Elise Biopharma, BOC Sciences, Isomerase Therapeutics, AGC Biologics, etc.

This report presents a comprehensive overview of the global Biomanufacturing and Fermentation Service market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • Strain Engineering Services
  • Fermentation Process Optimization
  • Analytical Testing & Quality Control Services
  • Fermentation CDMO Service

Segment by Stage

  • Laboratory
  • Pilot Scale
  • Large-scale Production

Segment by Application

  • Biopharmaceuticals
  • Industrial Biotechnology
  • Food and Functional Ingredients
  • Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Biomanufacturing and Fermentation Service market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Biopharmaceuticals, Industrial Biotechnology, Food and Functional Ingredients evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Biomanufacturing and Fermentation Service Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 15.1%
Regional growth momentum
Market share by segment
Key metrics
Base value
$8.38B
2025
Forecast
$22.4B
2032
CAGR
15.1%
2025–2032
Régions
5
global
Key companies
FUJIFILM BiotechnologiesElise BiopharmaBOC SciencesIsomerase TherapeuticsAGC BiologicsCentre for Process Innovation (CPI)Euroapi3PBIOVIAN
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
Strain Engineering ServicesFermentation Process OptimizationAnalytical Testing & Quality Control ServicesFermentation CDMO Service
By Application
BiopharmaceuticalsIndustrial BiotechnologyFood and Functional IngredientsOthers

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Strain Engineering Services
  • 3.1.3 Fermentation Process Optimization
  • 3.1.4 Analytical Testing & Quality Control Services
  • 3.1.5 Fermentation CDMO Service
  • 3.1.6 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Biopharmaceuticals
  • 4.1.3 Industrial Biotechnology
  • 4.1.4 Food and Functional Ingredients
  • 4.1.5 Others
  • 4.1.6 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 FUJIFILM Biotechnologies
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 Elise Biopharma
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 BOC Sciences
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 Isomerase Therapeutics
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 AGC Biologics
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 Centre for Process Innovation (CPI)
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 Euroapi
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 3PBIOVIAN
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 Abolis Biotechnologies
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 Evonik
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
  • 8.11 ScaleUp Bio Pte Ltd
  • 8.11.1 Company Overview
  • 8.11.2 Key Products & Segments
  • 8.11.3 Financial Performance (2023–2025)
  • 8.11.4 Business Strategy
  • 8.11.5 SWOT Analysis
  • 8.11.6 Strategic Implications (2026–2032)
  • 8.12 Olon Biotech
  • 8.12.1 Company Overview
  • 8.12.2 Key Products & Segments
  • 8.12.3 Financial Performance (2023–2025)
  • 8.12.4 Business Strategy
  • 8.12.5 SWOT Analysis
  • 8.12.6 Strategic Implications (2026–2032)
  • 8.13 Biocatalysts Ltd
  • 8.13.1 Company Overview
  • 8.13.2 Key Products & Segments
  • 8.13.3 Financial Performance (2023–2025)
  • 8.13.4 Business Strategy
  • 8.13.5 SWOT Analysis
  • 8.13.6 Strategic Implications (2026–2032)
  • 8.14 Manus Bio
  • 8.14.1 Company Overview
  • 8.14.2 Key Products & Segments
  • 8.14.3 Financial Performance (2023–2025)
  • 8.14.4 Business Strategy
  • 8.14.5 SWOT Analysis
  • 8.14.6 Strategic Implications (2026–2032)
  • 8.15 ADM
  • 8.15.1 Company Overview
  • 8.15.2 Key Products & Segments
  • 8.15.3 Financial Performance (2023–2025)
  • 8.15.4 Business Strategy
  • 8.15.5 SWOT Analysis
  • 8.15.6 Strategic Implications (2026–2032)
  • 8.16 Bio‑Technical Resources
  • 8.16.1 Company Overview
  • 8.16.2 Key Products & Segments
  • 8.16.3 Financial Performance (2023–2025)
  • 8.16.4 Business Strategy
  • 8.16.5 SWOT Analysis
  • 8.16.6 Strategic Implications (2026–2032)
  • 8.17 GEA
  • 8.17.1 Company Overview
  • 8.17.2 Key Products & Segments
  • 8.17.3 Financial Performance (2023–2025)
  • 8.17.4 Business Strategy
  • 8.17.5 SWOT Analysis
  • 8.17.6 Strategic Implications (2026–2032)
  • 8.18 Lonza
  • 8.18.1 Company Overview
  • 8.18.2 Key Products & Segments
  • 8.18.3 Financial Performance (2023–2025)
  • 8.18.4 Business Strategy
  • 8.18.5 SWOT Analysis
  • 8.18.6 Strategic Implications (2026–2032)
  • 8.19 WuXi Biologics
  • 8.19.1 Company Overview
  • 8.19.2 Key Products & Segments
  • 8.19.3 Financial Performance (2023–2025)
  • 8.19.4 Business Strategy
  • 8.19.5 SWOT Analysis
  • 8.19.6 Strategic Implications (2026–2032)
  • 8.20 Ajinomoto
  • 8.20.1 Company Overview
  • 8.20.2 Key Products & Segments
  • 8.20.3 Financial Performance (2023–2025)
  • 8.20.4 Business Strategy
  • 8.20.5 SWOT Analysis
  • 8.20.6 Strategic Implications (2026–2032)
  • 8.21 BIOVECTRA Inc.
  • 8.21.1 Company Overview
  • 8.21.2 Key Products & Segments
  • 8.21.3 Financial Performance (2023–2025)
  • 8.21.4 Business Strategy
  • 8.21.5 SWOT Analysis
  • 8.21.6 Strategic Implications (2026–2032)
  • 8.22 Nordmark Pharma GmbH
  • 8.22.1 Company Overview
  • 8.22.2 Key Products & Segments
  • 8.22.3 Financial Performance (2023–2025)
  • 8.22.4 Business Strategy
  • 8.22.5 SWOT Analysis
  • 8.22.6 Strategic Implications (2026–2032)
  • 8.23 Dakota BioWorx
  • 8.23.1 Company Overview
  • 8.23.2 Key Products & Segments
  • 8.23.3 Financial Performance (2023–2025)
  • 8.23.4 Business Strategy
  • 8.23.5 SWOT Analysis
  • 8.23.6 Strategic Implications (2026–2032)
  • 8.24 Andgel Industrial (Shanghai) Co
  • 8.24.1 Company Overview
  • 8.24.2 Key Products & Segments
  • 8.24.3 Financial Performance (2023–2025)
  • 8.24.4 Business Strategy
  • 8.24.5 SWOT Analysis
  • 8.24.6 Strategic Implications (2026–2032)
  • 8.25 Chengdu Yingde Biomedical
  • 8.25.1 Company Overview
  • 8.25.2 Key Products & Segments
  • 8.25.3 Financial Performance (2023–2025)
  • 8.25.4 Business Strategy
  • 8.25.5 SWOT Analysis
  • 8.25.6 Strategic Implications (2026–2032)
  • 8.26 Thermo Fisher Scientific
  • 8.26.1 Company Overview
  • 8.26.2 Key Products & Segments
  • 8.26.3 Financial Performance (2023–2025)
  • 8.26.4 Business Strategy
  • 8.26.5 SWOT Analysis
  • 8.26.6 Strategic Implications (2026–2032)
  • 8.27 Asymchem
  • 8.27.1 Company Overview
  • 8.27.2 Key Products & Segments
  • 8.27.3 Financial Performance (2023–2025)
  • 8.27.4 Business Strategy
  • 8.27.5 SWOT Analysis
  • 8.27.6 Strategic Implications (2026–2032)
  • 8.28 Danaher
  • 8.28.1 Company Overview
  • 8.28.2 Key Products & Segments
  • 8.28.3 Financial Performance (2023–2025)
  • 8.28.4 Business Strategy
  • 8.28.5 SWOT Analysis
  • 8.28.6 Strategic Implications (2026–2032)
  • 8.29 Sartorius
  • 8.29.1 Company Overview
  • 8.29.2 Key Products & Segments
  • 8.29.3 Financial Performance (2023–2025)
  • 8.29.4 Business Strategy
  • 8.29.5 SWOT Analysis
  • 8.29.6 Strategic Implications (2026–2032)
  • 8.30 Laurus Bio
  • 8.30.1 Company Overview
  • 8.30.2 Key Products & Segments
  • 8.30.3 Financial Performance (2023–2025)
  • 8.30.4 Business Strategy
  • 8.30.5 SWOT Analysis
  • 8.30.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

How big is the global Biomanufacturing and Fermentation Service market?
The global Biomanufacturing and Fermentation Service market is estimated at US$ 8.38 billion in 2025 (base year) and is projected to reach US$ 22.22 billion by 2032.
How fast is the Biomanufacturing and Fermentation Service market expected to grow?
The market is expected to grow at a CAGR of 15.1% from 2026 to 2032, expanding from US$ 8.38 billion in 2025 to US$ 22.22 billion in 2032, roughly 2.7 times its base-year value.
What does the Biomanufacturing and Fermentation Service market cover?
Biomanufacturing and fermentation services are a crucial supporting link in the modern biopharmaceutical and biotechnology industries. Their core lies in controlling the large-scale cultivation and production of microorganisms or cells under controlled environments to obtain target proteins, antibodies, vaccines, or functional biomolecules. The upstream fermentation stage involves cell line resuscitation, passage culture, and scale-up culture in large-scale bioreactors to ensure the expression and accumulation of the target product.
How is the Biomanufacturing and Fermentation Service market segmented by type?
By type, the market is segmented into Strain Engineering Services, Fermentation Process Optimization, Analytical Testing & Quality Control Services and Fermentation CDMO Service.
What are the key applications of Biomanufacturing and Fermentation Service?
Key applications covered include Biopharmaceuticals, Industrial Biotechnology, Food and Functional Ingredients and Others.
Which companies are profiled in the Biomanufacturing and Fermentation Service market report?
Key players profiled include FUJIFILM Biotechnologies, Elise Biopharma, BOC Sciences, Isomerase Therapeutics, AGC Biologics, Centre for Process Innovation (CPI), Euroapi and 3PBIOVIAN, among 30 companies covered in total.
What geographies does the Biomanufacturing and Fermentation Service market analysis include?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
Who should buy the Biomanufacturing and Fermentation Service market report?
The report is intended for manufacturers and solution providers, distributors and end users in Biopharmaceuticals, Industrial Biotechnology and Food and Functional Ingredients, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Biomanufacturing and Fermentation Service market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

Select a license
from 3 500,00 $US
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.